Results 221 to 230 of about 333,288 (246)

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Serious Adverse Events in Adult ICU Patients: A Substudy of the PATIENCE Cohort

Acta Anaesthesiologica Scandinavica, Volume 71, Issue 1, January 2027.
ABSTRACT Introduction Prokinetic agents are used to enhance upper gastrointestinal motility, but adverse events related to these agents are poorly described. We aimed to provide detailed epidemiological data on predefined serious adverse events (SAEs) in a cohort of adult intensive care unit (ICU) patients with and without prokinetic treatment.
Vera Crone, Morten Hylander Møller, Anders Granholm, Anders Perner, Waleed Alhazzani, Abdulrahman Al‐Fares, Johanna Hästbacka, Marlies Ostermann, Carmen A. Pfortmueller, Ricard Ferrer, Annika Reintam Blaser, Eric Keus, Wojciech Szczeklik, Mette Krag   +13 more
wiley   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dopamine Receptor Agonists in Current Clinical Use: Comparative Dopamine Receptor Binding Profiles Defined in the Human Striatum

Journal of Neural Transmission, 2003
T Arzberger, F Leblhuber, M Gerlach
exaly  

Inhibition of Dopamine Neuron Firing by Pramipexole, a Dopamine D3 Receptor-Preferring Agonist: Comparison to Other Dopamine Receptor Agonists

European Journal of Pharmacology, 1996
M F Piercey, M W Smith, Montford F Piercey   +2 more
exaly  

The Role of Dopamine Agonists in the Treatment of Depression in Patients With Parkinson’s Disease

Drugs, 2011
Albert F G Leentjens
exaly  

A Review of the Receptor-Binding and Pharmacokinetic Properties of Dopamine Agonists

Clinical Therapeutics, 2006
Sebastian Härtter
exaly